Related Suggestion
Fapon Biotech, a global leading IVD enterprise, has
signed an agreement with Stanford University to become an industry member of
the Stanford University Healthcare Innovation Lab (HIL) Affiliates Program.
This membership will provide Fapon Biotech with cutting-edge scientific
insights and further opportunities in precision medicine.
The
Stanford Healthcare Innovation Lab brings together the world’s leading
researchers to incubate cutting edge science that translates into real-world
applications. This affiliate program will accelerate the work in Healthcare Big
Data & Precision Medicine while providing exclusive insights and
opportunities to its members for advancements in healthcare. Under the
scientific direction of Dr. Michael Snyder, the Stanford W. Ascherman Professor
and Chair of the Genetics Department at Stanford Medicine, the Stanford
Healthcare Innovation Lab is changing the landscape of infectious disease,
diabetes, cancer, cardiovascular disease, aging, mental health, precision
diagnostics, cloud computing, multi-omics data standardization, real-time health
monitoring, AI/ML, and more. Dr. Snyder, who will serve as the liaison with
Fapon Biotech, has developed many cutting-edge technologies, co-founded
companies with >$6B market capital, and pioneered the longitudinal, baseline
profiling approach to measure every molecule and aspect of human health.
On July 2023, Dr. Michael Snyder hosted a visit of Ben He, President of Fapon Biotech
and Jilun Zhu, CFO & CIO of Fapon at the Stanford University Healthcare
Innovation Lab. The parties have well-aligned interest in the future of
medicine and healthcare, which will set a great foundation for further in-depth
collaborations. Leveraging on
leading healthcare technologies and industrial expertise from Stanford
University, Fapon Biotech aims to contribute to the advancement of healthcare
research and diagnostics innovation.
As a member
of the Stanford HIL affiliate program, Fapon Biotech will be at the forefront
of the lab’s latest research, engage with respective innovation lab experts,
and meet early startups with the potential to increase Fapon’s global
influence. In addition, Fapon Biotech has been invited to join Stanford HIL for
the Mental Healthcare Innovations Summit in November – an event launched last
year that brings together leaders across the mental health field in research,
health insurance, government, policy, advocacy, nonprofits, philanthropy, and
entrepreneurship to discuss the latest research, innovations advancing care,
and policy implementation.
